Interobserver variation in the endoscopic diagnosis of gastroduodenal ulcer scars: implications for clinical management of NSAIDs users

BMC Research Notes

Yoshikazu Kinoshita¹  Shunji Ishihara¹  Norihisa Ishimura¹  Nobuhiko Fukuba¹  Yasumasa Tada¹  Mayumi Okada¹  Takafumi Yuki²  Goichi Uno²  Yuji Amano² 

[1] Second Department of Internal Medicine, Shimane University, Faculty of Medicine, Izumo, Japan;Division of Endoscopy, Shimane University Hospital, Izumo, Japan

关键词: interobserver diagnostic agreement;    duodenal ulcer scar;    gastric ulcer scar;    proton pump inhibitor;    NSAIDs;   

Others  :  1167085
DOI  :  10.1186/1756-0500-4-409

 received in 2011-08-05, accepted in 2011-10-13,  发布年份 2011

【 摘 要 】

Background

A clinical history of peptic ulcer has been reported to be associated with a high rate of ulcer recurrence in nonsteroidal anti-inflammatory drug (NSAID) users. Therefore, it is a very important issue to precisely know the previous history prior to NSAIDs administration. To clarify the possible difficulty to identify the history, we determined the sensitivity and diagnostic concordance of endoscopy for the identification of ulcer scars indicative of previous clinical history of peptic ulcer diseases.

Methods

The first study enrolled 200 consecutive patients with a clinical history of gastric or duodenal ulcers previously confirmed by esophagogastroduodenoscopy. The sensitivity of endoscopy for identifying scars was determined for these patients. In the second study, the extent of interobserver agreement was determined for 47 endoscopists who identified ulcer scars in endoscopic photographs of 30 sites of previous active gastric ulcers and 30 sites of previous active duodenal ulcers. The kappa coefficient of reliability was calculated to measure the interobserver agreement on the diagnosis of ulcer scars.

Results

Out of 190 patients eligible for analysis, 104 (54.7%) were found to have gastric or duodenal ulcer scars on endoscopy; there were no gastric or duodenal ulcer scars seen in the remaining patients (45%). In the second study, the kappa values for endoscopic diagnosis of gastric and duodenal ulcer scars were 0.14 (95% CI 0.13-0.16) and 0.29 (95% CI 0.27-0.32), respectively. The addition of indigo-carmine chromoendoscopy did not provide a statistically significant improvement in diagnostic concordance in patients with gastric ulcer scar since the kappa value for chromoendoscopic diagnosis was 0.15; 95% CI 0.13-0.17 as low as for un-contrasted scars.

Conclusions

The sensitivity and concordance of endoscopic diagnosis of gastric and duodenal ulcer scars are not satisfactory for the use of endoscopy only to identify previous ulcer disease. To avoid the overlooking the previous clinical history of peptic ulcer diseases, the diagnosis of peptic ulcer scar has to be carefully done prior to NSAIDs administration.

【 授权许可】

   
2011 Amano et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Barkun AN, Bardou M, Kuipers EJ, Sung J, Hunt RH, Martel M, Sinclair P, International Consensus Upper Gastrointestinal Bleeding Conference Group: International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010, 152:101-113.
• [2]Clinard F, Bardou M, Sgro C, Lefevre N, Raphael F, Paille F, Dumas M, Hillon P, Bonithon-Kopp C: Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Clin Pharmacol 2001, 57:737-743.
• [3]Shiotani A, Sakakibara T, Yamanaka Y, Imamura H, Tarumi K, Manabe N, Manabe N, Kamada T, Kusunoki H, Hata J, Haruma K: Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol 2009, 44:126-131.
• [4]Miyake K, Kusunoki M, Shinji Y, Shindo T, Kawagoe T, Futagami S, Gudis K, Tsukui T, Nakajima A, Sakamoto C: Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol 2009, 44:113-120.
• [5]Lanza FL, Chan FK, Quigley EM: Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
• [6]Tsumura H, Fujita T, Tamura I, Morita Y, Yoshida M, Toyonaga T, Mukai H, Inokuchi H, Kutsumi H, Azuma T: Association between adherence to evidence-based guidelines for the prescription of non-steroidal anti-inflammatory drugs and the incidence of gastric mucosal lesions in Japanese patients. J Gastroenterol 2010, 45:944-951.
• [7]Sostres C, Gargallo CJ, Arroyo MT, Lanas A: Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 2010, 24:121-132.
• [8]Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP: Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther 2010, 32:1240-1248.
• [9]Laine L, Connors L, Griffin MR, Curtis SP, Kaur A, Cannon CP: Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther 2009, 30:767-774.
• [10]Koch M, Dezi A, Tarquini M, Capurso L: Prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal mucosal injury: risk factors for serious complications. Dig Liver Dis 2000, 32:138-151.
• [11]Scheiman JM, Hindley CE: Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010, 32:667-677.
• [12]García Rodríguez LA, Hernández-Díaz S, de Abajo FJ: Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
• [13]Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C: Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006, 101:701-710.
• [14]Goldstein JL, Huang B, Amer F, Christopoulos NG: Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther 2004, 26:1637-1643.
• [15]Tsai YW, Wen YW, Huang WF, Chen PF, Kuo KN, Hsiao FY: Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. J Gastroenterol 2011, 46:39-45.
• [16]Siegel S, Castellan NJ Jr: Nonparametric statistics for the behavioral sciences. Second edition. McGraw-Hill Book Co., New York, USA; 1988.
• [17]Amano Y, Ishimura N, Furuta K, Takahashi Y, Chinuki D, Mishima Y, Moriyama I, Fukuhara H, Ishihara S, Adachi K, Kinoshita Y: Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc 2006, 64:206-211.
• [18]Amano Y, Ishimura N, Furuta K, Okita K, Masaharu M, Azumi T, Ose T, Koshino K, Ishihara S, Adachi K, Kinoshita Y: Interobserver agreement on classifying endoscopic diagnoses of nonerosive esophagitis. Endoscopy 2006, 38:1032-1035.
• [19]McCarthy DM: Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol 2001, 15:755-773.
• [20]Sakaki N, Takemoto T: The relationship between endoscopic findings of gastric ulcer scar and ulcer relapse. J Clin Gastroenterol 1993, 17(Suppl 1):S64-S69.
• [21]Toljamo KT, Niemelä SE, Karttunen TJ, Karvonen AL, Lehtola JK: Clinical significance and outcome of gastric mucosal erosions: a long-term follow-up study. Dig Dis Sci 2006, 51:543-547.
• [22]Chang CC, Pan S, Lien GS, Liao CH, Chen SH, Cheng YS: Deformity of duodenal bulb, gastric metaplasia of duodenal regenerating mucosa and recurrence of duodenal ulcer: a correlated study. World J Gastroenterol 2005, 11:1802-1805.